Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Darolutamide is developed jointly by Bayer and Orion Corporation
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The service has already been initiated in Maharashtra but being net-based it is easily available for patients all across the country
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Subscribe To Our Newsletter & Stay Updated
